Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Mateon Therapeutics, Inc.
  6. Summary
    MATN   US57667K1097

MATEON THERAPEUTICS, INC.

(MATN)
  Report
 SummaryQuotesNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Estimated financial data (e) (USD)
Sales 2021 2,50 M - -
Net income 2021 -10,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,59x
Yield 2021 -
Sales 2022 5,50 M - -
Net income 2022 -7,40 M - -
Net Debt 2022 - - -
P/E ratio 2022 -11,7x
Yield 2022 -
Capitalization 64,6 M 64,6 M -
Capi. / Sales 2021 25,8x
Capi. / Sales 2022 11,7x
Nbr of Employees 16
Free-Float 67,9%
More Financials
Company
Oncotelic Therapeutics, Inc., formerly Mateon Therapeutics, Inc., is an immuno-oncology company. The Company is engaged in development of ribonucleic acid (RNA) therapeutics as well as small molecule drugs against cancer and infectious diseases. The CompanyÔÇÖs pipeline includes ArtiVeda/ArtiShield, OT-101, CA4P and Oxi4503. The ArtiVeda/ArtiShield is a derivative from the plant Artemisia. Its immuno-oncology drug... 
More about the company
Ratings of Mateon Therapeutics, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about MATEON THERAPEUTICS, INC.
07/20Oncotelic Therapeutics, Inc. Announces Board Changes
CI
07/20ONCOTELIC THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8..
AQ
07/02ONCOTELIC THERAPEUTICS : Entry into Securities Purchase Agreement and Issuance o..
PU
07/02ONCOTELIC THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unreg..
AQ
07/02Oncotelic Therapeutics, Inc. Announces Executive Changes
CI
06/15ONCOTELIC THERAPEUTICS : CLOSES COVID-19 CLINICAL TRIAL EARLY (Form 8-K)
PU
06/15ONCOTELIC THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
06/15ONCOTELIC THERAPEUTICS : Closes covid-19 clinical trial early.
AQ
06/15Oncotelic Therapeutics, Inc. Closes Covid-19 Clinical Trial Early
CI
05/25Oncotelic Therapeutics, Inc. announced that it has received $0.20375 million ..
CI
05/07ONCOTELIC THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unreg..
AQ
04/21ONCOTELIC THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
04/21ONCOTELIC THERAPEUTICS : Announces positive top line data for arti-19 clinical t..
AQ
04/19Oncotelic therapeutics, inc. announced synergy between ot-101 and il-2 (prole..
GL
04/15ONCOTELIC THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
More news
News in other languages on MATEON THERAPEUTICS, INC.

- No features available -

More news
Chart MATEON THERAPEUTICS, INC.
Duration : Period :
Mateon Therapeutics, Inc. Technical Analysis Chart | MATN | US57667K1097 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Last Close Price 0,18 $
Average target price 2,35 $
Spread / Average Target 1 243%
EPS Revisions
Managers and Directors
Vuong Trieu Chairman, President & Chief Executive Officer
Amit Bhupendra Shah Chief Financial Officer
Chulho Park Chief Technology Officer
Seymour H. Fein Chief Medical Officer
David Diamond Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MATEON THERAPEUTICS, INC.0.00%85
GILEAD SCIENCES, INC.18.01%85 134
WUXI APPTEC CO., LTD.32.49%71 226
REGENERON PHARMACEUTICALS19.60%57 013
BIONTECH SE251.15%55 555
VERTEX PHARMACEUTICALS-15.83%50 308